Who Paid My Doc
Research studies in the Open Payments record
139,921 studies have research funding reported against them. Being named on a study as a principal investigator is reported separately from being paid.
Studies
50 of 139,921- M20-051 No ClinicalTrials.gov identifier reported
- M20-070 No ClinicalTrials.gov identifier reported
- M20-070 NCT000000NA
- M20-098 No ClinicalTrials.gov identifier reported
- M20-098 ABBV-951 aPD NCT04750226
- M20-098 - Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No ClinicalTrials.gov identifier reported
- M20-103 No ClinicalTrials.gov identifier reported
- M20-124 NCT04417465
- M20-124 ABBV-CLS-579 Ph1 FIH Solid Tumors NCT04417465
- M20-124 - First In Human Study With ABBV-CLS-579 When Given Alone Or In Combination With Programmed Cell Death-1 Inhibitor In Participants With Locally Advanced Or Metastatic Tumors No ClinicalTrials.gov identifier reported
- M20-132 No ClinicalTrials.gov identifier reported
- M20-178 NCT04468984
- M20-178 - Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed Refractory Myelofibrosis No ClinicalTrials.gov identifier reported
- M20-186 NCT04451772
- M20-200 No ClinicalTrials.gov identifier reported
- M20-247 - Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis No ClinicalTrials.gov identifier reported
- M20-258 - Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma No ClinicalTrials.gov identifier reported
- M20-259 NCT04524611
- M20-259 - Study Comparing Intravenous (IV) Subcutaneous (SC) Risankizumab to IV SC Ustekinumab to Assess Change in Crohn Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn Disease (CD) No ClinicalTrials.gov identifier reported
- M20-262 - A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy No ClinicalTrials.gov identifier reported
- M20-350 - Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE) Pibrentasvir (PIB) No ClinicalTrials.gov identifier reported
- M20-356 - Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) No ClinicalTrials.gov identifier reported
- M20-429 Epcoritamab Ph1 R-R Aggressive Mature B-Cell Neoplasms Pediatric Patient NCT05206357
- M20-429 - Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab No ClinicalTrials.gov identifier reported
- M20-431 ABBV-CLS-484 Ph 1 2L Solid Tumors Study PTPN2i NCT04777994
- M20-431 - A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors No ClinicalTrials.gov identifier reported
- M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No ClinicalTrials.gov identifier reported
- M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No ClinicalTrials.gov identifier reported
- M20-621 Ph 3 DLBCL 1L Induction NCT05578976
- M20-638 Epcoritamab Ph3 R-R FL NCT05409066
- M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No ClinicalTrials.gov identifier reported
- M20-732 - Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis No ClinicalTrials.gov identifier reported
- M21-199 - Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No ClinicalTrials.gov identifier reported
- M21-201 A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine NCT05707949
- M21-201 - A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No ClinicalTrials.gov identifier reported
- M21-201 Atogepant Ph3 EM Peds (3101-307-002) NCT05711394
- M21-307 - Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No ClinicalTrials.gov identifier reported
- M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No ClinicalTrials.gov identifier reported
- M21-341 ATH Ph 2b Armour Thyroid vs Synthetic T4 (ATH-MD-01) (3014-301-002) NCT06345339
- M21-404 ABBV-400 Ph1 FIH Advanced Solid Tumors NCT05029882
- M21-416 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No ClinicalTrials.gov identifier reported
- M21-416 BOTOX Ph3 Pivotal MMP NCT06387394
- M21-417 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No ClinicalTrials.gov identifier reported
- M21-417 BOTOX Ph3 Pivotal MMP NCT06399718
- M21-446 - Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis No ClinicalTrials.gov identifier reported
- M21-459 - Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis Bladder Pain Syndrome (IC BPS) No ClinicalTrials.gov identifier reported
- M21-465 - Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No ClinicalTrials.gov identifier reported
- M21-465 Vraylar Ph3 Autism Spectrum Patients (2000-301-009) NCT05439616
- M21-471 Ph2b PoC Study (2068-201-008) NCT05216250
- M21-471 - Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor No ClinicalTrials.gov identifier reported